Form 4: Ventyx Biosciences Senior VP of Finance Acquires Stock Options

Roy Gonzales, Senior VP of Finance at Ventyx Biosciences, acquired stock options for 126,700 shares on January 2, 2025, according to a recent SEC filing.

Summary

• Roy Gonzales, Senior VP of Finance at Ventyx Biosciences, was granted stock options on January 2, 2025.
• The options are for a total of 126,700 shares of Ventyx Biosciences common stock.
• The exercise price for these options is $2.14 per share.
• The options vest monthly over a four-year period, starting from the vesting commencement date of January 2, 2025.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The granting of stock options to a senior executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The stock options will vest over the next four years, subject to the executive's continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 1/48th per month is a typical vesting structure for stock options.
• The exercise price of $2.14 is specific to Ventyx Biosciences and its current stock valuation.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning executive interests with company performance.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, Ventyx Biosciences, executive compensation, equity incentive